Clinical Study of SL19+22 CAR-T Cells for Relapsed or Refractory Non-Hodgkin Lymphoma

NCT05206071 · clinicaltrials.gov ↗

NA

Phase

UNKNOWN

Status

100

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-hodgkin's Lymphoma

Interventions

BIOLOGICAL: CD19+22 CAR-T cells

Sponsor

Hebei Senlang Biotechnology Inc., Ltd.